French pharma giant Sanofi said that international Phase 3 clinical tests of its Kevzara drug for serious Covid-19 cases had proved inconclusive and it was halting the trial.
The Phase 3 test - normally the last before official approval for use - "did not meet the primary or secondary evaluation criteria compared with a placebo, and in both cases, compared with established hospital care," it said in a statement.
Sanofi said neither it nor its American partner in developing the drug, Regeneron, "envisage further clinical tests of Kevzara for the treatment of Covid-19." Although Kevzara "did not give us the results we were hoping for, we are proud of the work done by our team," Sanofi global research head D.
Read more on rte.ie